{
  "abstract": "We read with great interest the SIMBA trial, a triple-blind, randomised, placebo-controlled superiority study of simvastatin versus placebo for prevention of recurrent acute pancreatitis (RAP) and acute-on-chronic inflammatory flares of chronic pancreatitis (CP).1 In the intention-to-treat analysis, recurrence occurred in 46.2% assigned to simvastatin vs 44.4% assigned to placebo (OR 1.07, 95% CI 0.43 to 2.66; p=0.88), with no difference in time to recurrence. New-onset diabetes occurred in four participants receiving simvastatin, raising safety questions. The investigators concluded that simvastatin did not reduce recurrent episodes or CP flares; importantly, the trial was terminated early after slow recruitment, and interim conditional power was very low, making statistical significance unlikely even with planned enrolment.",
  "authors": [
    {
      "affiliations": [
        "School of Medicine, Stanford University, Stanford, California, USA"
      ],
      "name": "Yi Jiang"
    },
    {
      "affiliations": [
        "Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China",
        "Johns Hopkins Medical Institutions, Baltimore, Maryland, USA"
      ],
      "name": "Jianing Li"
    },
    {
      "affiliations": [
        "Basic and Translational Pancreatic Research, Cedars Sinai Medical Center, Los Angeles, California, USA"
      ],
      "name": "Stephen J Pandol"
    },
    {
      "affiliations": [
        "School of Medicine, Stanford University, Stanford, California, USA"
      ],
      "name": "Walter Park"
    }
  ],
  "title": "Negative trial, positive lessons: refining endpoints and eligibility in RAP/CP prevention studies",
  "uid": "71adc5a0-aedb-52b8-b6ed-a9c4d662aaee"
}